Sales & Marketing News | pharmaphorum

News

BioMarin keeps but scales down Roctavian gene therapy ops

BioMarin Pharma has decided not to divest its haemophilia A gene therapy Roctavian, which has struggled to build much traction in the market, but is reining back its ambitions for the busin

News

Biopharma, finance vets launch $600m life sciences loan firm

There's a new source of funding for life sciences companies in town, providing credit as an alternative to other financing avenues such as venture capital.

News

Bayer CEO says recovery on track as key drug products shine

Bayer has joined its peers among European drugmakers with a hike in pharma forecasts for the year, as it recorded a rise in group sales, but lower profits for the second quarter.

News

Mallinckrodt sells Therakos unit on at a discount

Ireland-headquartered pharma group Mallinckrodt has agreed to divest its subsidiary Therakos to private equity firm CVC Capital Partners for $925 million, well below the $1.33 billion it pa

News

Actinium's radioligand filing plans scuppered by FDA

Shares in Actinium Pharmaceuticals have lost almost two-thirds of their value after the FDA asked for a second clinical trial before it would consider reviewing the company's Iomab-B radiol

News

FDA panel backs Zevra's arimoclomol, after earlier rejection

An FDA advisory committee has recommended approval of Zevra Therapeutics' arimoclomol for the ultra-rare disorder Niemann-Pick disease, three years after the regulator rejected the drug.

BioMarin keeps but scales down Roctavian gene therapy ops

Biopharma, finance vets launch $600m life sciences loan firm

Bayer CEO says recovery on track as key drug products shine

Mallinckrodt sells Therakos unit on at a discount

Actinium's radioligand filing plans scuppered by FDA

FDA panel backs Zevra's arimoclomol, after earlier rejection

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks